Delivery of biomolecules to PBMCs to modify an immune response
AssigneeSQZ Biotechnologies Company
InventorsArmon R. Sharei, Howard Bernstein, Scott Loughhead, Matthew Booty, Katarina Blagovic, Kelan Hlavaty, Defne Yarar, Emrah Ilker Ozay, Carolyne Kelly Smith
Life of this patent
Estimating the term…
Abstract
The present application provides peripheral blood mononuclear cells comprising an antigen, methods of manufacturing such PBMCs, and methods of using such PBMCs, such as for modulating an immune response in an individual. In some embodiments, the PBMCs are conditioned by incubating the PBMC in the presence of an adjuvant.
Claims38
A conditioned plurality of modified PBMCs comprising an antigen intracellularly, wherein the antigen is exogenous to the modified PBMCs, and wherein the plurality of modified PBMCs have been incubated with an adjuvant for about 4 hours to less than 24 hours to condition the plurality of modified PBMCs such that the conditioned plurality of modified PBMCs are capable of inducing an in vivo T cell immune response, and wherein the in vivo T cell immune response is at least about 2-fold greater than that induced by corresponding non-conditioned plurality of modified PBMCs.
A conditioned plurality of modified PBMCs comprising an antigen and a first adjuvant intracellularly, wherein the antigen and the first adjuvant are exogenous to the modified PBMCs, wherein the plurality of modified PBMCs have been incubated with a second adjuvant for about 4 hours to less than 24 hours to condition the plurality of modified PBMCs such that the conditioned plurality of modified PBMCs are capable of inducing an in vivo T cell immune response, wherein the in vivo T cell immune response is at least about 2-fold greater than that induced by corresponding non-conditioned plurality of modified PBMCs, and wherein the first adjuvant and the second adjuvant are not the same.
A method for generating a conditioned plurality of PBMCs comprising an antigen intracellularly, comprising incubating a plurality of PBMCs with an adjuvant for about 4 hours to less than 24 hours to condition the plurality of PBMCs such that the conditioned plurality of PBMCs are capable of inducing an in vivo T cell immune response, wherein the in vivo T cell immune response is at least about 2-fold greater than that induced by corresponding non-conditioned plurality of PBMCs, and wherein the antigen is intracellularly delivered to the plurality of PBMCs before or after the incubating.
Dependencies are inferred from the claim text.